Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients - A randomized, double-blind, placebo-controlled trial

被引:90
作者
Kuffner, EK
Dart, RC
Bogdan, GM
Hill, RE
Casper, E
Darton, L
机构
[1] Denver Hlth Author, Rocky Mt Poison & Drug Ctr, Denver, CO 80230 USA
[2] Denver Hlth Author, Denver Hlth med Ctr, Dept Psychiat, Denver, CO 80230 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80262 USA
关键词
D O I
10.1001/archinte.161.18.2247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Retrospective reports suggest that therapeutic doses of acetaminophen may be associated with fulminant hepatic failure and death in alcoholic patients. Millions of patients use acetaminophen; the prevalence of alcoholism in the United States is 5% to 10%. Objective: To determine if hepatic injury was associated with maximal therapeutic dosing of acetaminophen to chronic alcohol abuse patients immediately following cessation of alcohol intake (the presumed time of maximal vulnerability). Methods: Patients entering an alcohol detoxification center were enrolled in a randomized, double-blind, placebo-controlled trial. Exclusion criteria were baseline values of aspartate or alanine amino transferase greater than 120 U/L, international normalized ratio greater than 1.5, serum acetaminophen level greater than 20 mg/L, or a history of ingesting more than 4 g/d of acetaminophen. Acetaminophen, 1000 mg, or placebo was administered orally 4 times daily for 2 consecutive days and liver test results were monitored for 2 more days. Acetaminophen was not administered until the alcohol had been eliminated. Results: There were 102 patients in the acetaminophen-treated group and 99 patients in the placebo-treated (control) group. Demographic data, alcohol history, and baseline blood test results were similar in both groups. The mean (SD) aspartate aminotransferase level on day 4 was 38.0 +/- 26.7 U/L in the acetaminophen-treated group and 37.5 +/- 27.6 U/L in the placebo-treated group. There were 4 patients in the acetaminophen-treated group and 5 in the placebo-treated group who developed an increase in their serum aspartate aminotransferase level to greater than 120 U/L; it did not exceed 200 U/L in any patient. The mean (SD) international normalized ratio on day 4 was 0.96 +/- 0.09 in the acetaminophen-treated group and 0.98 +/- 0.11 in the placebo-treated group. Conclusion: Repeated administration of the maximum recommended daily doses of acetaminophen to longterm alcoholic patients was not associated with evidence of liver injury.
引用
收藏
页码:2247 / 2252
页数:6
相关论文
共 21 条
  • [1] INTERACTION OF ACUTE ETHANOL ADMINISTRATION WITH ACETAMINOPHEN METABOLISM AND TOXICITY IN RATS FED ALCOHOL CHRONICALLY
    ALTOMARE, E
    LEO, MA
    LIEBER, CS
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1984, 8 (04) : 405 - 408
  • [2] NUTRITIONAL ASSESSMENT - A COMPARISON OF CLINICAL JUDGMENT AND OBJECTIVE MEASUREMENTS
    BAKER, JP
    DETSKY, AS
    WESSON, DE
    WOLMAN, SL
    STEWART, S
    WHITEWELL, J
    LANGER, B
    JEEJEEBHOY, KN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (16) : 969 - 972
  • [3] BANDA PW, 1982, RES COMMUN CHEM PATH, V38, P57
  • [4] ACETAMINOPHEN IN CHRONIC LIVER-DISEASE
    BENSON, GD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (01) : 95 - 101
  • [5] CRITCHLEY JAJH, 1982, BRIT J CLIN PHARMACO, V13, pP276
  • [6] Dart R C, 2000, Am J Ther, V7, P123, DOI 10.1097/00045391-200007020-00009
  • [7] INCREASED METABOLISM OF ACETAMINOPHEN IN CHRONICALLY ALCOHOLIC PATIENTS
    GIRRE, C
    HISPARD, E
    PALOMBO, S
    NGUYEN, C
    DALLY, S
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1993, 17 (01) : 170 - 173
  • [8] GRANT BF, 1994, ALCOHOL HEALTH RES W, V18, P243
  • [9] KRISTENSON H, 1982, BRIT J ADDICT, V77, P297
  • [10] GLUTATHIONE DEFICIENCY IN ALCOHOLICS - RISK FACTOR FOR PARACETAMOL HEPATOTOXICITY
    LAUTERBURG, BH
    VELEZ, ME
    [J]. GUT, 1988, 29 (09) : 1153 - 1157